Cargando…
Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects
ABSTRACT: LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212710/ https://www.ncbi.nlm.nih.gov/pubmed/33382916 http://dx.doi.org/10.1111/cts.12968 |
_version_ | 1783709690321960960 |
---|---|
author | Patel, Dipak R. Urva, Shweta Ho, Stephen Buckman, Cody J. Ma, Yanfei Lim, Jean Sissons, Sean E. Zuniga, Mary S. Philips, Diane Cox, Karen Dairaghi, Daniel J. |
author_facet | Patel, Dipak R. Urva, Shweta Ho, Stephen Buckman, Cody J. Ma, Yanfei Lim, Jean Sissons, Sean E. Zuniga, Mary S. Philips, Diane Cox, Karen Dairaghi, Daniel J. |
author_sort | Patel, Dipak R. |
collection | PubMed |
description | ABSTRACT: LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with LY2775240 led to significant reductions in TNFα production, a marker of PDE4 engagement upon immune activation, in both nonclinical models. In the first part of a 2‐part first‐in‐human randomized study, a wide dose range of LY2775240 was safely evaluated and found to be well‐tolerated with common adverse events (AEs) of nausea, diarrhea, and headache. No serious AEs were reported. The pharmacokinetic profile of LY2775240 was well‐characterized, with a half‐life that can support once‐a‐day dosing. An ex vivo pharmacodynamic (PD) assay demonstrated dose‐dependent PDE4 target engagement as assessed by reduction in TNFα production. A 20 mg dose of LY2775240 led to near‐maximal TNFα inhibition in this PD assay in the first part of the study and was selected for comparison with the clinical dose of apremilast (30 mg) in the crossover, second part of this study. The 20 mg dose of LY2775240 demonstrated sustained maximal (50%–80%) inhibition of TNFα over all timepoints over the 24‐h duration. The comparator apremilast achieved peak inhibition of ~ 50% at only 4 h postdose with a return to about 10% inhibition within 12 h of dosing. In summary, the nonclinical data and safety, tolerability, and PK/PD data in healthy subjects supports further investigation of LY2775240 in inflammatory indications. STUDY HIGHLIGHTS: WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? This is the first report of an ex vivo PD assay that has been systematically implemented in a PDE4 inhibitor Phase 1 study. Early investigation of exposure‐response relationships versus a comparator can support evaluation of clinically meaningful doses of investigational agents. |
format | Online Article Text |
id | pubmed-8212710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82127102021-06-25 Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects Patel, Dipak R. Urva, Shweta Ho, Stephen Buckman, Cody J. Ma, Yanfei Lim, Jean Sissons, Sean E. Zuniga, Mary S. Philips, Diane Cox, Karen Dairaghi, Daniel J. Clin Transl Sci Research ABSTRACT: LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with LY2775240 led to significant reductions in TNFα production, a marker of PDE4 engagement upon immune activation, in both nonclinical models. In the first part of a 2‐part first‐in‐human randomized study, a wide dose range of LY2775240 was safely evaluated and found to be well‐tolerated with common adverse events (AEs) of nausea, diarrhea, and headache. No serious AEs were reported. The pharmacokinetic profile of LY2775240 was well‐characterized, with a half‐life that can support once‐a‐day dosing. An ex vivo pharmacodynamic (PD) assay demonstrated dose‐dependent PDE4 target engagement as assessed by reduction in TNFα production. A 20 mg dose of LY2775240 led to near‐maximal TNFα inhibition in this PD assay in the first part of the study and was selected for comparison with the clinical dose of apremilast (30 mg) in the crossover, second part of this study. The 20 mg dose of LY2775240 demonstrated sustained maximal (50%–80%) inhibition of TNFα over all timepoints over the 24‐h duration. The comparator apremilast achieved peak inhibition of ~ 50% at only 4 h postdose with a return to about 10% inhibition within 12 h of dosing. In summary, the nonclinical data and safety, tolerability, and PK/PD data in healthy subjects supports further investigation of LY2775240 in inflammatory indications. STUDY HIGHLIGHTS: WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? WHAT QUESTION DID THIS STUDY ADDRESS? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? This is the first report of an ex vivo PD assay that has been systematically implemented in a PDE4 inhibitor Phase 1 study. Early investigation of exposure‐response relationships versus a comparator can support evaluation of clinically meaningful doses of investigational agents. John Wiley and Sons Inc. 2021-02-13 2021-05 /pmc/articles/PMC8212710/ /pubmed/33382916 http://dx.doi.org/10.1111/cts.12968 Text en © 2020 Eli Lilly and Company. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Patel, Dipak R. Urva, Shweta Ho, Stephen Buckman, Cody J. Ma, Yanfei Lim, Jean Sissons, Sean E. Zuniga, Mary S. Philips, Diane Cox, Karen Dairaghi, Daniel J. Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title | Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title_full | Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title_fullStr | Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title_full_unstemmed | Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title_short | Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
title_sort | characterization of ly2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212710/ https://www.ncbi.nlm.nih.gov/pubmed/33382916 http://dx.doi.org/10.1111/cts.12968 |
work_keys_str_mv | AT pateldipakr characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT urvashweta characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT hostephen characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT buckmancodyj characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT mayanfei characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT limjean characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT sissonsseane characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT zunigamarys characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT philipsdiane characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT coxkaren characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects AT dairaghidanielj characterizationofly2775240aselectivephosphodiesterase4inhibitorinnonclinicalmodelsandinhealthysubjects |